{"id":992326,"date":"2026-08-07T16:05:13","date_gmt":"2026-08-07T20:05:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\/"},"modified":"2026-08-07T16:05:13","modified_gmt":"2026-08-07T20:05:13","slug":"nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\/","title":{"rendered":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans"},"content":{"rendered":"<h2>\nConference Call 8:30 a.m. ET, Monday, August 10, 2026<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>MIAMI, Aug.  07, 2026  (GLOBE NEWSWIRE) &#8212; NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (&#8220;NRx Pharmaceuticals&#8221;, the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and Q&amp;A session on Monday, August 10, 2026 at 8:30 a.m. Eastern Time to discuss the FDA&#8217;s completion of first-cycle review of the Company&#8217;s ANDA for preservative-free ketamine, announced earlier today.<\/p>\n<p>Participating on the call will be Jonathan Javitt, MD, MPH, Founder and Chief Executive Officer; Glenn Tyson, Chief Commercial Officer; and Chaim Hurvitz, Director, former director of Teva and President of the Teva International Group. Questions will cover both the regulatory path to approval and the Company&#8217;s commercial plans.<\/p>\n<p>A live webcast of the conference call will be available on the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z7mSa6tO0V2ShGI28Jwmjo1Aj_oqlAAeMlwwbiaf6LcKhJLlgbCHY5d1A3drftRCjgcqLUc89_N4hoXL1QSySx2Meah7c1018h-7xu1iO_8VDfoV-atpXLjrq0pQ37TS\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.nrxpharma.com\/events<\/a>. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-800-864-5102 or internationally 1-646-394-9810. A replay of the webcast will be available on the Company\u2019s website following the event.<\/p>\n<p>\n        <strong>About NRx Pharmaceuticals, Inc.<\/strong>\n      <\/p>\n<p>NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine\/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of suicidal ideation in depression, including bipolar depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner\u2019s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression.<\/p>\n<p>\n        <strong>Notice Regarding Forward-Looking Statements<\/strong>\n      <\/p>\n<p>The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cintend,\u201d \u201clook forward,\u201d and other similar expressions among others. These statements relate to future events or to the Company\u2019s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company\u2019s actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company\u2019s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company\u2019s current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company\u2019s operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company\u2019s most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC\u2019s website at http:\/\/www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<p>\n        <strong>For further information:<\/strong>\n      <\/p>\n<p>\n        <strong><br \/>\n          <em>Brian Korb<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Managing Partner, astr partners<br \/>(917) 653-5122<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PSGNfyUmFKQOtl_-_XwvVDzXE14-MwXNO2k2bsw3XRMaXj9iUNpqkpvqdIbGdLhQBr95baVZ_EwMcPJWwFfsUvn9p40DdrdbxMqWRzSqwzuBCE1mFOgMvB_zMNrU9W0w\" rel=\"nofollow\" target=\"_blank\">brian.korb@astrpartners.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNjE1MiM3NzY1NjE3IzIwODQxMjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTYwMzUzNTAtZDQxYy00ZmI0LWJkOGUtNGU4NTkzNDg2M2IyLTEwOTU2OTMtMjAyNi0wOC0wNy1lbg==\/tiny\/NRx-Pharmaceuticals-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Conference Call 8:30 a.m. ET, Monday, August 10, 2026 MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) &#8212; NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (&#8220;NRx Pharmaceuticals&#8221;, the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and Q&amp;A session on Monday, August 10, 2026 at 8:30 a.m. Eastern Time to discuss the FDA&#8217;s completion of first-cycle review of the Company&#8217;s ANDA for preservative-free ketamine, announced earlier today. Participating on the call will be Jonathan Javitt, MD, MPH, Founder and Chief Executive Officer; Glenn Tyson, Chief Commercial Officer; and Chaim Hurvitz, Director, former director of Teva and President of the Teva International Group. Questions will cover both the regulatory path to approval and the Company&#8217;s commercial plans. A live &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-992326","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Conference Call 8:30 a.m. ET, Monday, August 10, 2026 MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) &#8212; NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (&#8220;NRx Pharmaceuticals&#8221;, the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and Q&amp;A session on Monday, August 10, 2026 at 8:30 a.m. Eastern Time to discuss the FDA&#8217;s completion of first-cycle review of the Company&#8217;s ANDA for preservative-free ketamine, announced earlier today. Participating on the call will be Jonathan Javitt, MD, MPH, Founder and Chief Executive Officer; Glenn Tyson, Chief Commercial Officer; and Chaim Hurvitz, Director, former director of Teva and President of the Teva International Group. Questions will cover both the regulatory path to approval and the Company&#8217;s commercial plans. A live &hellip; Continue reading &quot;NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-07T20:05:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNjE1MiM3NzY1NjE3IzIwODQxMjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans\",\"datePublished\":\"2026-08-07T20:05:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\\\/\"},\"wordCount\":689,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNjE1MiM3NzY1NjE3IzIwODQxMjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\\\/\",\"name\":\"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNjE1MiM3NzY1NjE3IzIwODQxMjI=\",\"datePublished\":\"2026-08-07T20:05:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNjE1MiM3NzY1NjE3IzIwODQxMjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNjE1MiM3NzY1NjE3IzIwODQxMjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\/","og_locale":"en_US","og_type":"article","og_title":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans - Market Newsdesk","og_description":"Conference Call 8:30 a.m. ET, Monday, August 10, 2026 MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) &#8212; NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (&#8220;NRx Pharmaceuticals&#8221;, the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and Q&amp;A session on Monday, August 10, 2026 at 8:30 a.m. Eastern Time to discuss the FDA&#8217;s completion of first-cycle review of the Company&#8217;s ANDA for preservative-free ketamine, announced earlier today. Participating on the call will be Jonathan Javitt, MD, MPH, Founder and Chief Executive Officer; Glenn Tyson, Chief Commercial Officer; and Chaim Hurvitz, Director, former director of Teva and President of the Teva International Group. Questions will cover both the regulatory path to approval and the Company&#8217;s commercial plans. A live &hellip; Continue reading \"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-07T20:05:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNjE1MiM3NzY1NjE3IzIwODQxMjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans","datePublished":"2026-08-07T20:05:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\/"},"wordCount":689,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNjE1MiM3NzY1NjE3IzIwODQxMjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\/","name":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNjE1MiM3NzY1NjE3IzIwODQxMjI=","datePublished":"2026-08-07T20:05:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNjE1MiM3NzY1NjE3IzIwODQxMjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNjE1MiM3NzY1NjE3IzIwODQxMjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/992326","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=992326"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/992326\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=992326"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=992326"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=992326"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}